(Total Views: 490)
Posted On: 10/13/2025 11:55:25 AM
Post# of 157994
It was only confusing because I didn't realize you didn't know Leron had been turned down for BTD.
Nader told us in one of his videos. Also, this was from a doc CYDY filed with the SEC:
And then later in the same doc:
Nader told us in one of his videos. Also, this was from a doc CYDY filed with the SEC:
Quote:
In January 2020, the Company filed for Breakthrough Therapy designation (“BTD”) with the FDA to use leronlimab as adjuvant therapy for the treatment of mTNBC. The FDA requested the Company to file for a pre-BTD meeting due to the small number of patients.
And then later in the same doc:
Quote:
On January 28, 2020, the Company awarded approximately 11.7 million performance shares to certain of its directors and executive officers outside of the 2012 Plan (“January 2020 Performance Shares”), which awards would vest and be settled in shares of common stock of the Company if the Company achieved FDA Breakthrough Therapy designation for cancer within six months of the award date and if, and to what extent, certain other requirements have been met. The awards were forfeited on July 28, 2020 when the performance conditions were not met.
(9)
(0)
